Prescriber Survey to Assess Boxed Warnings Perceptions

Survey Questionnaire: HCV

(Questions used for pre-testing condition are included at the end)

Introductory Script:

Thank you for your participation in this survey. The first few questions will focus on chronic hepatitis C viral infection, also known as chronic HCV.

**// *Note*: Where [drug] is indicated, respondents in the chronic HCV condition will be randomly assigned to see Harvoni, Mavyret, or Zepatier.//**

**//PROGRAMMING NOTE: Do not allow participants to go back on any screen.//**

**Question Type:** Single Punch

**Question 1**

How experienced are you with treating chronic HCV?

**Variable Label:** Q1 Familiarity with treating HCV

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all experienced |
| 2 | Slightly experienced |
| 3 | Somewhat experienced |
| 4 | Experienced |
| 5 | Very experienced |
| -99 | Refused |

**Question Type:** Single Punch

**Question 2**

How many patients do you typically see for treatment of chronic HCV?

**Variable Label:** Q2 Number of patients typically seen

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | One or two patients a week, or fewer |
| 2 | Several patients a week |
| 3 | Several patients a day |
| --98 | Unsure/Don’t know |
| --99 | Refused |

**Question Type:** Single Punch

**Question 3**

In general, how important is treating chronic HCV with the goal of a curing it?

**Variable Label:** Q3 Importance of curing HCV

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all important |
| 2 | Slightly important |
| 3 | Somewhat important |
| 4 | Important |
| 5 | Very important |
| -98 | Unsure/Don’t know |
| -99 | Refused |

**Question Type:** Single Punch

**Question 4A**

Which of the following is true of your prescribing direct-acting antivirals (DAA) for the treatment of chronic HCV?

**Variable Label:** Q4A Experience prescribing DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | I have written new prescriptions for this product |
| 2 | I have only prescribed a refill for this product |
| 3 | I have never prescribed this product |
| -98 | Unsure/don’t know |
| -99 | Refused |

**//SKIP 4B if 4A = 2, 3, 4, or -98//**

**Question Type:** Single Punch

**Question 4B**

On average, how often do you prescribe direct-acting antivirals (DAA) for treatment of chronic HCV?

**Variable Label:** Q4B Frequency of prescribing DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | I prescribe this product one or more times a week |
| 2 | I prescribe this product a few times a month |
| 3 | I prescribe this product a few times a year |
| -98 | Unsure/Don’t know |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 5**

Which of the following other treatments would you recommended or prescribe in a typical month (Select all that apply)?

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Value Text** | **Variable Label** |
| Q5\_1 | Direct-acting antivirals (e.g., Harvoni, Epclusa, Mavyret, Vosevi, Zepatier) | Q5\_1 Typical treatment: DAA |
| Q5\_2 | Multi-pill regimen(s) (e.g., PEG/Riba therapy) | Q5\_2 Typical treatment: Multi pills |
| Q5\_3 | Interferon | Q5\_3 Typical treatment: Interferon |
| Q5\_4 | Ribavirin | Q5\_4 Typical treatment: Ribavirin |
| Q5\_5 | Other (specify) | Q5\_5 Typical treatment: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

For the next few questions, we would like you to consider your patients who have a positive diagnosis of chronic HCV and have symptoms of spider-like blood vessels on their skin, jaundice, dark-colored urine, and are bruising easily.

For this section, also consider the whole class of fixed-dose combination drugs/direct-acting antivirals.

**//[SHOW SCENARIO AT THE TOP OF THE SCREEN FOR QUESTION 6]//**

**Question Type:** Single Punch

**Question 6**

How likely are you to discuss direct-acting antivirals as a potential option for these patients?

**Variable Label:** Q6 Likelihood of discussing DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Very unlikely |
| 2 | Unlikely |
| 3 | Somewhat likely |
| 4 | Likely |
| 5 | Very likely |
| -99 | Refused |

**Question Type:** Single Punch

**Question 7**

Which of the following statements describe your assessment of the safety of direct-acting antivirals used to treat HCV?

**Variable Label:** Q7 Risk assessment of DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Risks are minimal for almost all patients |
| 2 | Risks are minimal for most patients, but are significant for some patients |
| 3 | Risks are significant for most patients |
| 4 | I am not familiar enough with direct-acting antivirals to make an assessment |
| -99 | Refused |

**Question Type:** Single Punch

**Question 8**

Which statement best describes your general perspective on the benefits versus risks of direct-acting antivirals for patients with chronic HCV?

**Variable Label:** Q8 Benefits/risks of DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | The benefits of direct-acting antivirals outweigh the risks for most patients |
| 2 | The benefits of direct-acting antivirals outweigh the risks for some, but not most, patients |
| 3 | The benefits of direct-acting antivirals outweigh the risks for very few patients |
| 4 | I am not familiar enough with direct-acting antivirals to make an assessment |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 9**

Which of the following factors play the most important role when deciding whether or not to prescribe direct-acting antivirals to a patient with chronic HCV? Please choose the three factors that you consider to be most important. **[//Multi-punch//]**

//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//

**[RANDOM ORDER EXCEPT FOR OTHER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q9\_1 | Considerations of this patient’s ability to take the product as prescribed | Q9\_1 Factors: Patient ability to use |
| Q9\_2 | This patient’s understanding and comfort with the risks of this medication | Q9\_2 Factors: Understanding and comfort with risks |
| Q9\_3 | This patient’s previous experience with treatments | Q9\_3 Factors: Patient’s previous experience |
| Q9\_4 | This patient’s medical and health context (e.g., medical history, comorbidities) | Q9\_4 Factors: Medical and health context |
| Q9\_5 | Considerations of this patient’s access to the product (e.g., cost, insurance) | Q9\_5 Factors: Patient access |
| Q9\_6 | Extent, duration, and severity of patient’s symptoms | Q9\_6 Factors: Symptoms |
| Q9\_7 | Patient’s preference for a mode of administration | Q9\_7 Factors: Patient preference for administration |
| Q9\_8 | Potential duration of treatment use/course | Q9\_8 Factors: Duration |
| Q9\_9 | Other (please specify) | Q9\_9 Factors: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Multi Punch

**Question 10**

What are the top three comments or questions you have heard from patients about using direct-acting antivirals to treat chronic HCV? (Select up to three.) **[//Multi-punch//]**

//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//

**[RANDOM ORDER, EXCEPT FOR OTHER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q10\_1 | Undergoing treatment when the patient is currently asymptomatic | Q10\_1 Comments top 3: Undergoing treatment |
| Q10\_2 | Hearing positive things about how well direct-acting antivirals work | Q10\_2 Comments top 3: Hearing positive things |
| Q10\_3 | Concerns about specific side effects | Q10\_3 Comments top 3: Side effects |
| Q10\_4 | Concerns about insurance coverage or cost | Q10\_4 Comments top 3: Insurance coverage/cost |
| Q10\_5 | Hearing negative things about how well direct-acting antivirals work | Q10\_5 Comments top 3: Hearing negative things |
| Q10\_6 | Pros about the mode of administration | Q10\_6 Comments top 3: Pros mode of administration |
| Q10\_7 | Cons about the mode of administration | Q10\_7 Comments top 3: Cons mode of administration |
| Q10\_8 | Concerns about being able to complete treatment course | Q10\_8 Comments top 3: General concerns re: treatment |
| Q10\_9 | Other (specify) | Q10\_9 Comments top 3: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Multi Punch

**Question 11**

What are the top three topics that you prioritize when talking to your patients about direct-acting antivirals as a treatment option? **[//Multi-punch//]**

//PROGRAMMING NOTE: ALLOW PARTICIPANT TO SELECT UP TO THREE ANSWERS//

**[RANDOM ORDER EXCEPT FOR LAST OPTION] [//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q11\_1 | How the product works | Q11\_1 Talking top 3: How product works |
| Q11\_2 | Expected benefits of the product | Q11\_2 Talking top 3: Expected benefits |
| Q11\_3 | Common side effects of the product | Q11\_3 Talking top 3: Common side effects |
| Q11\_4 | Rare but serious side effects of the product | Q11\_4 Talking top 3: Rare serious effects |
| Q11\_5 | Patient’s medical history (e.g., personal history or family history, possible co-morbidities) | Q11\_5 Talking top 3: Medical history |
| Q11\_6 | The importance of using the product as directed | Q11\_6 Talking top 3: Importance of use as directed |
| Q11\_7 | Other (Specify) | Q11\_7 Talking top 3: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**//PROGRAMMING NOTE: If Q11D selected, display Q11\_RISK. OTHERWISE, PROCEED TO Q12 //**

**Question Type:** Open End Essay

**Question 11\_RISKS**

You said that you discuss rare but serious side effects of the product. What potential side effects do you discuss?

**Variable Label: Q11** Side effects discussed

**Question Type:** Multi Punch

**Question 12**

How do you most commonly monitor your patients for potential safety risks and side effects after prescribing direct-acting antivirals for HCV? Select all that apply. **[//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q12\_1 | I schedule routine follow-up appointments with patients. | Q12\_1 Monitor: Follow-up appointment |
| Q12\_2 | I instruct patients to get bloodwork before follow-up appointment. | Q12\_2 Monitor: Bloodwork |
| Q12\_3 | I instruct patients to call and schedule an appointment if they experience side effects. | Q12\_3 Monitor: Appointment if side effects |
| Q12\_4 | I leave it to the patient to follow up if they feel a need to. | Q12\_4 Monitor: Leave up to patient |
| Q12\_5 | A follow-up appointment is not necessary. | Q12\_5 Monitor: Follow-up not necessary |
| Q12\_6 | Other (specify) | Q12\_6 Monitor: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Grid

**Question 13**

How often do you look for information about direct-acting antivirals from the following sources:

**[RANDOM ORDER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable TextText** | **Variable Label** |
| Q13\_ 1 | Medical journals | Q13\_1 Info: Medical journals |
| Q13\_2 | Medical websites or software (e.g. UpToDate, Epocrates, Medscape) | Q13\_2 Info: Medical websites or software |
| Q13\_3 | Drug company/pharmaceutical representatives or their website | Q13\_3 Info: Drug company rep or website |
| Q13\_4 | Go online/use a search engine (e.g., Google) | Q13\_4 Info: Online search |
| Q13\_5 | Professional medical societies (e.g., publications, guidelines) | Q13\_5 Info: Professional medical societies |
| Q13\_6 | Conferences | Q13\_6 Info: Conferences |
| Q13\_7 | Discussion with colleagues (e.g., in person, email) | Q13\_7 Info: Discussion w/ colleagues |
| Q13\_8 | FDA website or other FDA sources of information (e.g., email, alerts) | Q13\_8 Info: FDA |
| Q13\_9 | Other government agencies (e.g., NIH, CDC) | Q13\_9 Info: Other government agencies |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Never |
| 2 | Rarely |
| 3 | Sometimes |
| 4 | Often |

**//[SHOW QUESTION AT THE TOP OF THE SCREEN FOR QUESTION 14]//**

The next question refers to boxed warnings on the product labeling for direct-acting antivirals.

**Question Type:** Multi Punch

**Question 14**

In your opinion, what is the primary role of a boxed warning? *Choose up to three options.*

**//Random Order, except last three**

//PROGRAMMING NOTE: ALLOW PARTICIPANT TO UP TO SELECT THREE ANSWERS//

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q14\_1 | To highlight the most serious potential risks of the product | Q14\_1 BW Primary Role: Highlight most serious risks |
| Q14\_2 | To provide information that should be factored into a decision to prescribe the product | Q14\_2 BW Primary Role: Provide prescribing information |
| Q14\_3 | To provide an overview of the safety profile of the product | Q14\_3 BW Primary Role: Provide safety profile overview |
| Q14\_4 | To disclose clinical trial and other product safety testing information | Q14\_4 BW Primary Role: Clinical trial and safety testing |
| Q14\_5 | To provide information that prescribers should be communicating to patients | Q14\_5 BW Primary Role: Info to communicate to patients |
| Q14\_6 | To provide information on how to safely use the product | Q14\_6 BW Primary Role: Info on how to safely use product |
| Q14\_7 | I do not see a role for them | Q14\_7 BW Primary Role: No role for BW |
| Q14\_8 | Other (specify) | Q14\_8 BW Primary Role: Other |
| Q14\_9 | Unsure/Don’t know | Q14\_9 BW Primary Role: Unsure/Don’t know |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 0 | Not included |

**//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE//**

The next set of questions will ask you more specifically about the boxed warning and the prescribing information for direct-acting antivirals to treat chronic HCV. This boxed warning appears on all prescription direct-acting antiviral products.

**//PROGRAMMING NOTE: “NEXT” BUTTON TO PROCEED TO Q15//**

**Question Type:** Single Punch

**Question 15**

How would you rate your familiarity with the boxed warning for direct-acting antivirals?

**Variable Label:** Q15 Familiarity with BW for DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all familiar |
| 2 | Slightly familiar |
| 3 | Somewhat familiar |
| 4 | Familiar |
| 5 | Very familiar |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 16**

Which of the following risks do you recall being included in the boxed warning for direct-acting antivirals? Select all that apply.

**[RANDOM ORDER EXCEPT FOR LAST TWO OPTIONS]** **[//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable TextText** | **Variable Label** |
| Q16\_1 | Hepatitis B reactivation in coinfected patients | Q16\_1 Risks: Hepatitis B |
| Q16\_2 | Bradycardia | Q16\_2 Risks: Bradycardia |
| Q16\_3 | Interaction with beta blockers | Q16\_3 Risks: Interaction with beta blockers |
| Q16\_4 | Asthenia | Q16\_4 Risks: Asthenia |
| Q16\_5 | Visual abnormalities | Q16\_5 Risks: Visual abnormalities |
| Q16\_6 | Elevated blood pressure | Q16\_6 Risks: Elevated blood pressure |
| Q16\_7 | Stroke | Q16\_7 Risks: Stroke |
| Q16\_8 | None of the above | Q16\_8 Risks: None of the above |
| Q16\_9 | Other (specify) | Q16\_9 Risks: Other |


|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 2 | Not included |
| 3 | Don’t know |


**//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW BOXED WARNING//**

We would like to show you some of the boxed warning information for [DAA drug], which is available in the FDA-approved prescribing information. The boxed warning information appears on the labeling for all direct-acting antivirals. Please consider [DAA drug] to serve as an example that represents the direct-acting antiviral drug class as a whole. Please take a few moments to review this information.

**//PROGRAMMING NOTE: SHOW THE BOXED WARNING ON ITS OWN PAGE//**

[View boxed warning information][[1]](#footnote-1)[[2]](#footnote-2)[[3]](#footnote-3)





****

**//PROGRAMMING NOTE: HAVE A “NEXT” BUTTON AT THE BOTTOM OF THE BOXED WARNING PAGE TO PROCEED TO QUESTION 17//**

**Question Type:** Single Punch

**Question 17**

How useful is the information in the boxed warning for [DAA drug]?

**Variable Label:** Q17 Usefulness of BW for DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all useful |
| 2 | Slightly useful |
| 3 | Somewhat useful |
| 4 | Useful |
| 5 | Very useful |
| -99 | Refused |

**Question Type:** Single Punch

**Question 18**

What is your assessment of the way the risks of [DAA drug] are framed in the boxed warning?

**Variable Label:** Q18 Assessment of risk framing in DAA BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Strongly understates risk |
| 2 | Somewhat understates risk |
| 3 | Provides appropriate assessment of risk information |
| 4 | Somewhat overstates risk |
| 5 | Strongly overstates risk |
| 6 | Other (specify) |
| -99 | Refused |

**Question Type:** Single Punch

**Question 19**

Which statement best reflects your opinion on the relative benefits versus risks of direct-acting antivirals for patients with chronic HCV?

**Variable Label:** Q19 Assessment of benefits versus risks Post-BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | The benefits of direct-acting antivirals outweigh the risks for most patients |
| 2 | The benefits of direct-acting antivirals outweigh the risks for some, but not most, patients |
| 3 | The benefits of direct-acting antivirals outweigh the risks for very few patients |
| 4 | I am not familiar enough with direct-acting antivirals to make an assessment |
| -99 | Refused |

//[SHOW SCENARIO AT THE TOP OF THE SCREEN FOR QUESTION 19\_HBV]//

Imagine this scenario when answering the following question:

In prescreening, you determine that your patient with HCV has previously received treatment for an HBV infection. The patient tests positive for HBV antibodies, but has no signs of currently active infection.

**Question Type:** Single Punch

**Question 19\_HBV**

Which of the following best describes your course of action for treating this patient?

**Variable Label:** Q19\_HBV Treating patient using DAA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | I would not prescribe [DAA drug] to this patient |
| 2 | I might still prescribe [DAA drug] to this patient, but would consider other options first |
| 3 | I would prescribe [DAA drug] to this patient but monitor her more carefully than other patients |
| 4 | I would refer this patient to someone else for treatment |
| 5 | Other (specify) |
| -98 | Unsure/Don’t know |
| -99 | Refused |

[PIPE ALL RESPONSES TO Q19\_HBV\_OTH]

**Question Type: Open End Essay**

**Question 19\_HBV\_OE**

You said you would take the following course of action for treating this patient:

**[**PIPE SELECTED RESPONSE FROM Q19\_HBV]

Please briefly elaborate on the reason(s) for your response.

[SOFT PROMPT]

**Variable Label:** Q19\_HBV\_OE Reason for treatment option

**Question Type:** Multi Punch

**Question 20**

What would improve the boxed warning for [DAA drug] in your opinion? (Select all that apply.)

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q20\_1 | Nothing, the warning is fine the way it is | Q20\_1 Improve BW: Nothing |
| Q20\_2 | Better evidence to support risk information | Q20\_2 Improve BW: Better risk info evidence |
| Q20\_3 | Decrease the amount of information given/fewer words | Q20\_3 Improve BW: Decrease amount of info/shorten |
| Q20\_4 | Simpler language | Q20\_4 Improve BW: Simpler language |
| Q20\_5 | Formatting improvements (e.g., use of boldface) | Q20\_5 Improve BW: Formatting |
| Q20\_6 | Increase the amount of information (e.g., statistics, more details) | Q20\_6 Improve BW: Increase amount of info |
| Q20\_7 | Other (Specify) | Q20\_7 Improve BW: Other (specify) |
| Q20\_8 | Unsure/Don’t know | Q20\_8 Improve BW: Unsure/Don’t know |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 2 | Not included |

**Question Type:** Open End Essay

**Question 21**

Please provide any specific feedback on the boxed warning information for [DAA drug].

**Variable Label:** Q21 Specific feedback on DAA BW information

//PROGRAMMING NOTE: SHOW SENTENCE ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW Q22//

Please now consider boxed warnings in general, not only the one you saw for [DAA drug].

**Question Type:** Grid

**Question 22**

To what degree do you agree or disagree with the following statements about boxed warnings in general (in other words, across all classes of prescription drugs)?

**[RANDOM ORDER for 1-6]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q22\_1 | Boxed warnings are very common on the products that I prescribe | Q22\_1 Agree/Disagree: BW are very common on products I prescribe |
| Q22\_2 | Boxed warnings do not generally factor heavily into my decisions on whether to prescribe a product | Q22\_2 Agree/Disagree: BW do not generally factor heavily |
| Q22\_3 | I think carefully before prescribing a product with a boxed warning if other treatments are available | Q22\_3 Agree/Disagree: I think carefully before prescribing BW product if others available |
| Q22\_4 | I counsel my patients differently when prescribing a product with a boxed warning | Q22\_4 Agree/Disagree: Counsel patients differently with BW |
| Q22\_5 | My patients rarely know whether a product would have a boxed warning or not | Q22\_5 Agree/Disagree: Patients rarely know if product has BW |
| Q22\_6 | My patients are worried or scared when they see boxed warnings | Q22\_6 Agree/Disagree: Patients worried/scared when they see BW |
| Q22\_7 | Other (specify) | Q22\_7 |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Strongly disagree |
| 2 | Disagree |
| 3 | Neither agree nor disagree |
| 4 | Agree |
| 5 | Strongly agree |
| -98 | Unsure/Don’t know |

**Question Type:** Single Punch

**Question 23**

How favorable is your opinion of boxed warnings *in general* (across all classes of prescription drugs)?

**Variable Label:** Q23 General favorability of BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Very unfavorable |
| 2 | Somewhat unfavorable |
| 3 | Neither unfavorable nor favorable |
| 4 | Somewhat favorable |
| 5 | Very favorable |
| -98 | Unsure/Don’t know |
| -99 | Refused |

**Question Type:** Open End Essay

**Question 24**

In general, what suggestions do you have on how to better use boxed warnings as a tool to highlight important safety information?

**Variable Label:** Q24 Suggestions for better using BW to highlight safety info

**//DISPLAY TEXT//**

**We would like your feedback on the survey that you completed. This will help FDA improve the survey for future use with healthcare providers.**

**Question Type**: Single Punch

**Question P1**

Were you able to complete the survey in one session?

**Variable Label:** P1 One session completion

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Yes |
| 0 | No |

**Question Type**: Open End Essay

**Question P2**

Did you rely on other sources (e.g., Google, colleagues, etc.) to answer questions you found difficult to answer? If yes, please explain.

**Variable Label:** P2 Other sources

**Question Type**: Open End Essay

**Question P3**

Were there any questions you had difficulty answering? If yes, please explain.

**Variable Label:** P3 Difficulty answering question

**Question Type**: Open End Essay

**Question P4**

What other suggestions of feedback about this survey would you like to share?

**Variable Label:** P4 Other feedback

Thank you for taking this survey. Your time is greatly appreciated.

1. NIH NLM (2019). LABEL: HARVONI- ledipasvir and sofosbuvir tablet, film coated. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075> [↑](#footnote-ref-1)
2. NIH NLM (2020). LABEL: MAVYRET- glecaprevir and pibrentasvir tablet, film coated. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf99777-0401-9095-8645-16c6e907fcc0> [↑](#footnote-ref-2)
3. NIH NLM (2018). LABEL: ZEPATIER- elbasvir and grazoprevir tablet, film coated. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=164dc02a-9180-426a-b8b5-04ab39d2bbd4> [↑](#footnote-ref-3)